Comparative Pharmacology
Head-to-head clinical analysis: AZTREONAM versus CAYSTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZTREONAM versus CAYSTON.
AZTREONAM vs CAYSTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aztreonam is a monobactam antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP3) of Gram-negative bacteria, leading to cell death.
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is active against Gram-negative aerobic bacteria including Pseudomonas aeruginosa.
1-2 g IV or IM every 6-8 hours; maximum 8 g/day.
75 mg (one vial) inhaled via nebulizer three times daily, each dose approximately 4 hours apart.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; prolonged to 6-9 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateAztreonam + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aztreonam."
Approximately 2.0–2.5 hours in patients with normal renal function. In patients with moderate renal impairment (CrCl 30–49 mL/min), half-life may be prolonged to ~4.5 hours.
Renal: 60-70% unchanged via glomerular filtration and tubular secretion; nonrenal: 30-40% (hepatic metabolism to inactive metabolites and biliary excretion, with <1% fecal elimination).
Primarily renal; >99% of the absorbed dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Category C
Category C
Monobactam Antibiotic
Monobactam Antibiotic